Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease

Go Back to All Clinical Trials

Hypertonic Saline for Treatment of Pulmonary Mycobacterium Avium Complex (MAC) Disease

Brief description of study

The purpose of this study is to learn more about whether nebulized hypertonic saline can help improve symptoms and clearance of mycobacteria. Hypertonic saline (7% solution) for inhalation is sometimes prescribed to patients with Mycobacterium Avium Complex(MAC) lung infections. The researchers also want to learn how much of a burden this treatment is for participants with MAC. Hypertonic saline (7%) will be called the “study drug” throughout this form. The use of the hypertonic saline (7%) for pulmonary NTM has not been approved by the Food and Drug Administration (FDA) because we do not know enough about it. Therefore, in this study, its use is considered investigational. Hypertonic saline has been used in those with other lung problems(bronchiectasis, cystic fibrosis), but has not been studied in those with MAC lung infections.

Clinical Study Identifier: s21-00922

ClinicalTrials.gov Identifier: NCT04921943

Principal Investigator: Doreen J Addrizzo-Harris.

Other Investigator: Rudra Ramanathan.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies